바이오테크 보도자료
-
- Sales of Needle-Free Injectors Set to Rise by 11.4% CAGR as Application Soars in Response to Increasing Cases of Diabetes Worldwide: Future Market Insights
- According to the latest study by Future Market Insights (FMI), global Needle-Free Injectors’ sales are expected to reach US$ 12.3 Bn in 2021, surging at 11.4% CAGR during the forecast period (2021-2031). Nee...
- 2022년 01월 12일
-
- New UltimusPlus-NX Fluid Dispensers Improve Operational Efficiency by Allowing Remote Programming Directly from a PLC
- Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces the UltimusPlus-NX fluid dispenser. This fluid dispenser provides Ethernet connection wit...
- 2022년 01월 12일
-
- Industrial Air Compressor Market to Reach US$ 26.7 Bn as Application in Oil & Gas Transportation Burgeons: Future Market Insight
- Future Market Insight’s (FMI’s) latest study on the industrial air compressor market provides riveting insights into the key factors and opportunities augmenting the growth trajectory in the market. It also ...
- 2022년 01월 11일
-
- Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare Conference
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today confirmed the company is positioned for growth in the mid- and long-term with the potential to deliver incremental revenue growth an...
- 2022년 01월 11일
-
- Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire Adaptate Biotherapeutics (“Adaptate”), a UK company focused on developing antibody-b...
- 2022년 01월 11일
-
- QUANTA Dialysis Technologies Appoints Meghan Fitzgerald and Leslie Norwalk to Board of Directors
- QUANTA Dialysis Technologies Ltd (“QUANTA” or the “Company”), a medical technology company committed to making dialysis more accessible with its SC+ hemodialysis system, today announced that Meghan Fitzgeral...
- 2022년 01월 11일
-
- Iksuda Therapeutics Deepens Clinical Pipeline Through Licensing Agreement for Her2 Antibody Drug Conjugate Programme From LegoChem Biosciences
- Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced further expansion of its differentiated ADC pipeline through ...
- 2022년 01월 10일
-
- Black & Veatch Designs First-of-a-Kind Advanced R&D Facility for Cultivated Seafood in Singapore
- Black & Veatch collaborated with Shiok Meats for the conceptual design and layout of their first-of-a-kind advanced research and development facility for cultivated seafood, officially opened by Singapore’s ...
- 2022년 01월 10일
-
- Mary Kay Inc. & Mary Kay Ash FoundationSM Celebrate 2021 Year-End Highlights
- Mary Kay Inc., a global entrepreneurship development company and advocate for corporate social responsibility and sustainability, today released its year-end highlights. In 2021, Mary Kay Inc. continued its ...
- 2022년 01월 10일
-
- AIT Worldwide Logistics Combines Southern California Teams in Newly Constructed, State-of-the-Art Los Angeles Facility
- Today, global supply chain solutions leader AIT Worldwide Logistics celebrated the grand opening of a new, modern facility in a popular Los Angeles freight forwarding corridor. The location will soon be the ...
- 2022년 01월 06일
-
- FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
- Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for a ci...
- 2022년 01월 06일
-
- ANANDA Scientific Announces FDA approval of the IND for the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)
- ANANDA Scientific Inc., (a biotech pharma company) today announced approval by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating ...
- 2022년 01월 04일
-
- Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0176 in Prostate Cancer
- Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the compan...
- 2021년 12월 27일
전시회
